Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess Reactogenicity & Safety of a Booster of Either Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) & a Dose of Mencevax ACWY at 24-30 Mths (Open Label)

NCT00228917 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00228917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00228917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess Reactogenicity & Safety of a Booster of Either Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) & a Dose of Mencevax ACWY at 24-30 Mths (Open Label)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 16, 2005
Completion date
January 20, 2006
Enrollment
798 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, diphtheria-tetanus-pertussis-hepatitis b-haemophilus influenzae type b-neisseria meningitidis vaccin, haemophilus influenzae type b, hepatitis b, tetanus, whole cell pertussis